Mechanism of action<unk>  is an integrase strand transfer inhibitor. This means it blocks the HIV's enzyme integrase, thereby preventing its genome from being integrated into the human cells' DNA. As this is a necessary step for the virus to replicate, its further spread is hampered. Pharmacokinetics<unk>  glucuronide, the main metabolite in human bile and urine When taken by mouth,<unk>  reaches highest blood plasma levels after three hours. Taking the drug together with food slightly increases its concentrations in the blood, but this is not clinically relevant. After injection into the muscle,<unk>  is slowly absorbed into the bloodstream, reaching its highest blood plasma levels after about seven days. Over 99% of the substance are bound to plasma proteins. The drug is inactivated in the body by glucuronidation, mainly by the enzyme UGT1A1, and to a much lesser extent by UGT1A9. More than 90% of the circulating substance are the unchanged<unk> , however. The biological half-life is 41 hours for the tablets and 5.6 to 11.5 weeks for the injection. Elimination has only been studied for oral administration: Most of the drug is eliminated via the faeces in unchanged form (47%). It is not known how much of this amount comes from the bile, and how much was not absorbed in the first place. (The bile actually contains the glucuronide, but this could be broken up again in the gut lumen to give the parent substance that is observed in the faeces.) To a lesser extent it is excreted via the urine (27%), almost exclusively as the glucuronide. Pharmacogenomics UGT1A1 poor metabolizers have 1.3- to 1.5-fold increased<unk>  concentrations in the body. This is not considered clinically significant.
Cabotegravir
Maribavir
Saquinavir
Elvitegravir
Dolutegravir
Fosamprenavir
Fostemsavir
Elbasvir